Bill Ackman goes to Congress
Reuters
Ackman sits on the board of the embattled company, and is one of its major shareholders. In 2014 he helped Valeant with its failed bid to acquire Allergan Pharmaceuticals.
Valeant's outgoing CEO, Michael Pearson, and its former interim CEO, Howard Schiller will also testify before the Senate Committee on Aging.
The hearing has been scheduled since December, when the committee called on Valeant and three other pharmaceutical firms to answer for their drug pricing practices. At that point, Valeant had been under government scrutiny for some time, and that combined with accusations from a short seller sent the company's stock down around 70%.
The government is most concerned with Valeant's business model. The company pioneered the practice of using tax inversions to lower costs, cutting research and development, and growing through acquisitions.
"This year alone, Americans are expected to spend more than $328 billion on prescription drugs," said the Aging Committee in a statement. "Of this amount, individuals will pay about $50 billion out-of-pocket. The federal government will pick up another $110 billion in payments through Medicare, Medicaid, Veterans Affairs, and other programs."
The hearing starts at 3:30 PM EST.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Markets extend gains for 5th session; Sensex revisits 74k
- Top 10 tourist places to visit in Darjeeling in 2024
- India's forex reserves sufficient to cover 11 months of projected imports
- ITC plans to open more hotels overseas: CMD Sanjiv Puri
- 7 Indian dishes that are extremely rich in calcium